Concepedia

Lanfang Bai

LB

Statistics

Publications

7

Citations

979

H-Index

7

Active since

2004

Affiliations

University of California, Davis(Current)

Pfizer (United States)

Yale University

Lanfang Bai is an author at University of California, Davis specializing in src family kinase inhibitors, oncology, and molecular oncology.

Publications per year

2004–2012

7

Publications

7

Thioredoxin-2 Inhibits Mitochondria-Located ASK1-Mediated Apoptosis in a JNK-Independent Manner

Rong Zhang, Rafia S. Al‐Lamki, Lanfang Bai et al. · Circulation Research · 2004 · 253 citations · Full text

, , +16

Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530

Y-M Chang, Lanfang Bai, Sijia Liu et al. · Oncogene · 2008 · 186 citations

, , +14

Hsp90–Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis

Rong Zhang, Dianhong Luo, Lanfang Bai et al. · Oncogene · 2005 · 177 citations

, , +14

Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9

Javier Chaparro‐Riggers, Liang Hong, Rachel M. DeVay et al. · Journal of Biological Chemistry · 2012 · 165 citations · Full text

, , +17

Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates

Liang Hong, Javier Chaparro‐Riggers, Pavel Strop et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 105 citations

, , +16

1–5 of 7